- Hillstream BioPharma ( NASDAQ: HILS ) reported initial results from a study evaluating HSB-1216 in combination with Merck' ( NYSE: MRK ) Keytruda (pembrolizumab) in KRAS G12C-mutated non-small cell lung cancer (NSCLC) cells Calu-1.
- The company said the study showed significantly greater tumor inhibition of Calu-1 cells, when grown with human PBMCs (SEB-activated) and treated with HSB-1216 and pembrolizumab.
- "We are greatly encouraged by the initial results showing crosstalk and synergy between an established and validated immuno-oncology pathway, anti-PD-1, and Ferroptosis, a new emerging iron-dependent cell death pathway and mechanism of action for HSB-1216," said Hillstream's CEO Randy Milby.
- Hillstream noted that HSB-1216 — which is expected to enter clinical trials in 2023 — targets ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) of drug resistant cancers.
- HILS +71.19% to $2.02 premarket Feb. 10
For further details see:
Hillstream stock surges ~70% as HSB-1216, Keytruda combo shows promise in lung cancer cells